Gibbens D T, Triolo J, Yu T, Depalma J, Iglasias J, Castner D
Department of Cardiovascular and Interventional Radiology, Community Medical Center, 99 Highway 37 West, Toms River, NJ 08755, USA.
Tech Vasc Interv Radiol. 2001 Jun;4(2):122-6. doi: 10.1016/s1089-2516(01)90007-1.
Maintaining hemodialysis grafts remains a difficult problem. Before the early 1990s, graft declotting was usually performed in the surgical suite. Percutaneous declotting has been evolving since the mid-1980s. Initially, a low-dose thrombolytic infusion of streptokinase through a single catheter was used. Crossing catheters with a higher-dose infusion of urokinase was then introduced. This technique was modified with the adjunctive use of pharmacomechanical techniques with the use of compliant balloons and the adjunctive use of heparin. The advent of the "lyse-and-wait" technique provided a simpler and quicker way to declot thrombosed grafts by using urokinase, with similar outcomes. Since the removal of urokinase from the market, multiple mechanical devices have been used with similar success. Recent reports concerning the use of newer-generation thrombolytic agents report similar outcomes, with a reduction in total cost.
维持血液透析移植物仍然是一个难题。在20世纪90年代初之前,移植物解凝通常在手术室进行。自20世纪80年代中期以来,经皮解凝技术不断发展。最初,通过单根导管进行低剂量链激酶溶栓输注。随后引入了使用高剂量尿激酶的交叉导管技术。该技术通过使用顺应性球囊的药物机械技术辅助以及肝素辅助使用进行了改进。“溶解并等待”技术的出现提供了一种更简单、更快的方法,通过使用尿激酶来解凝血栓形成的移植物,效果相似。自从尿激酶退市以来,多种机械装置也取得了类似的成功。最近有关使用新一代溶栓剂的报告显示效果相似,且总成本有所降低。